Voorheis steps down at Advanced NMR

Article

William Voorheis of Advanced NMR has become the latest chief executive to leave a medical imagingcompany after posting 1994 annual results. Advanced NMR announcedthis month that Voorheis is vacating his positions as presidentand COO of the Wilmington,

William Voorheis of Advanced NMR has become the latest chief executive to leave a medical imagingcompany after posting 1994 annual results. Advanced NMR announcedthis month that Voorheis is vacating his positions as presidentand COO of the Wilmington, MA, firm. He will continue to workwith the company in a consulting capacity and remains a directorof Advanced NMR and its subsidiary, Advanced Mammography Systems.

The announcement came 10 days after Advanced NMR posted 1994numbers that saw its revenues increase 173% and its net loss drop42% (SCAN 4/12/95). Voorheis is the third medical imaging executivein the past two months to have lost his job within weeks of releasing1994 results, following Alan Margulis of MMI Medical and DavidRose of OEC Medical Systems (SCAN 3/29/95 and 3/1/95).

An Advanced NMR spokesperson said Voorheis had done an "excellent"job at the firm, but the company felt it needed new blood to moveon to the next level of sales and production. Advanced NMR marketsthe InstaScan echo-planar imaging package and its Advanced MammographySystems subsidiary is developing the Aurora dedicated MR mammographyscanner.

Advanced NMR chairman and CEO Jack Nelson has been appointedacting president of both Advanced NMR and Advanced MammographySystems. Vice president of sales and marketing Robert Kwolyk hasassumed Voorheis' COO duties.

In other Advanced NMR news, the company said that in conjunctionwith Advanced Mammography Systems it has developed a new MR mammographyfat-suppression technique to distinguish tumor from normal fattybreast tissue. The method reduces breast imaging times to undersix minutes, according to the company.

Recent Videos
Improving Access to Nuclear Imaging: An Interview with SNMMI President Jean-Luc C. Urbain, MD, PhD
SNMMI: 18F-Piflufolastat PSMA PET/CT Offers High PPV for Local PCa Recurrence Regardless of PSA Level
SNMMI: NIH Researcher Discusses Potential of 18F-Fluciclovine for Multiple Myeloma Detection
SNMMI: What Tau PET Findings May Reveal About Modifiable Factors for Alzheimer’s Disease
Emerging Insights on the Use of FES PET for Women with Lobular Breast Cancer
Can Generative AI Reinvent Radiology Reporting?: An Interview with Samir Abboud, MD
Mammography Study Reveals Over Sixfold Higher Risk of Advanced Cancer Presentation with Symptom-Detected Cancers
Combining Advances in Computed Tomography Angiography with AI to Enhance Preventive Care
Study: MRI-Based AI Enhances Detection of Seminal Vesicle Invasion in Prostate Cancer
What New Research Reveals About the Impact of AI and DBT Screening: An Interview with Manisha Bahl, MD
Related Content
© 2025 MJH Life Sciences

All rights reserved.